EyePoint, Inc. (FRA:PV3B)
Germany · Delayed Price · Currency is EUR | Market Cap | 985.77M +278.9% |
| Revenue (ttm) | 26.72M -27.5% |
| Net Income | -197.56M |
| EPS | -2.70 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 11.50 |
| Previous Close | 11.80 |
| Day's Range | 11.50 - 11.50 |
| 52-Week Range | 4.69 - 15.32 |
| Beta | n/a |
| RSI | 49.14 |
| Earnings Date | May 1, 2026 |
About EyePoint
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ... [Read more]
Financial Performance
In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with seriou...
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or misleading information about EyePoint and its lead experimental eye drug.
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Ca...
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint Appoints Michael Campbell as Chief Commercial Officer
– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversight of ...
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-20...
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track ...
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 –
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first pat...
EyePoint Announces Pricing of Public Offering
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 –
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician an...
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community –
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest –
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patien...
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
– Enrollment continues to exceed expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing con...
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives o...